(Q28371191)

English

TP53 Deleterious Mutation

genetic variant

DELETERIOUS MUTATION

In more languages

Statements

sequence variant

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/221

deleterious mutation

0 references

human chromosome 17

genomic assembly

Genome assembly GRCh37

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/221

7571720

genomic assembly

Genome assembly GRCh37

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/221

7590856

genomic assembly

Genome assembly GRCh37

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/221

biological variant of

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/221

positive therapeutic predictor for

adjuvant therapy

determination method

CIViC evidence level B

CIViC 2-star trust rating

medical condition treated

non-small-cell lung carcinoma

statement disputed by

Prognostic and Predictive Effect of TP53 Mutations in Patients with Non-Small Cell Lung Cancer from Adjuvant Cisplatin-Based Therapy Randomized Trials: A LACE-Bio Pooled Analysis

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1148

Prognostic and Predictive Effect of TP53 Mutations in Patients with Non-Small Cell Lung Cancer from Adjuvant Cisplatin-Based Therapy Randomized Trials: A LACE-Bio Pooled Analysis

determination method

CIViC evidence level B

CIViC 2-star trust rating

medical condition treated

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1170

TP53 mutational status is predictive of pazopanib response in advanced sarcomas

negative therapeutic predictor for

determination method

CIViC evidence level B

CIViC 3-star trust rating

medical condition treated

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/2966

Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia

negative prognostic predictor for

head and neck squamous cell carcinoma

determination method

CIViC evidence level B

CIViC 3-star trust rating

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/517

TP53 disruptive mutations lead to head and neck cancer treatment failure through inhibition of radiation-induced senescence.

non-small-cell lung carcinoma

determination method

CIViC evidence level B

CIViC 4-star trust rating

statement disputed by

Prognostic and Predictive Effect of TP53 Mutations in Patients with Non-Small Cell Lung Cancer from Adjuvant Cisplatin-Based Therapy Randomized Trials: A LACE-Bio Pooled Analysis

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1147

Prognostic and Predictive Effect of TP53 Mutations in Patients with Non-Small Cell Lung Cancer from Adjuvant Cisplatin-Based Therapy Randomized Trials: A LACE-Bio Pooled Analysis

Identifiers

CIViC variant ID

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/221

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28371191&oldid=2014798810"